Your browser doesn't support javascript.
loading
Influence of FLG loss-of-function mutations in host-microbe interactions during atopic skin inflammation.
Oláh, Peter; Szlávicz, Eszter; Kuchner, Marcus; Nemmer, Jana; Zeeuwen, Patrick; Lefèvre-Utile, Alain; Fyhrquist, Nanna; Prast-Nielsen, Stefanie; Skoog, Tiina; Serra, Angela; Rodríguez, Elke; Raap, Ulrike; Meller, Stephan; Gyulai, Rolland; Hupé, Philippe; Kere, Juha; Levi-Schaffer, Francesca; Tsoka, Sophia; Alexander, Helen; Nestle, Frank O; Schröder, Jens M; Weidinger, Stephan; van den Bogaard, Ellen; Soumelis, Vassili; Greco, Dario; Barker, Jonathan; Lauerma, Antti; Ranki, Annamari; Andersson, Björn; Alenius, Harri; Homey, Bernhard.
Afiliação
  • Oláh P; Department of Dermatology, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany; Department of Dermatology, Venereology and Oncodermatology, Medical Faculty, University of Pécs, Hungary.
  • Szlávicz E; Department of Dermatology, Venereology and Oncodermatology, Medical Faculty, University of Pécs, Hungary.
  • Kuchner M; Department of Dermatology, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
  • Nemmer J; Department of Dermatology, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
  • Zeeuwen P; Department of Dermatology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
  • Lefèvre-Utile A; Université de Paris, Inserm, U976 HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Assistance Publique-Hôpitaux de Paris (APHP), General Pediatric and Pediatric Emergency Department, Jean Verdier Hospital, Bondy, France.
  • Fyhrquist N; Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Prast-Nielsen S; Centre for Translational Microbiome Research (CTMR), Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
  • Skoog T; Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden.
  • Serra A; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Institute of Biosciences and Medical Technologies (BioMediTech), Tampere, University, Finland.
  • Rodríguez E; Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Raap U; Department of Dermatology, University Hospital Oldenburg, Germany.
  • Meller S; Department of Dermatology, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany.
  • Gyulai R; Department of Dermatology, Venereology and Oncodermatology, Medical Faculty, University of Pécs, Hungary.
  • Hupé P; INSERM U900, CNRS UMR144, Institut Curie, Mine Paris Tech, Paris, France.
  • Kere J; Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden; Stem Cells and Metabolism Research Program, Folkhälsan Research Institute, University of Helsinki, Helsinki, Finland.
  • Levi-Schaffer F; Pharmacology and Experimental Therapeutics Unit, Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
  • Tsoka S; Department of Informatics, Faculty of Natural and Mathematical Sciences, Kings College London, London, United Kingdom.
  • Alexander H; St John's Institute of Dermatology, Faculty of Medicine and Life Sciences, Kings College London, London, United Kingdom.
  • Nestle FO; St John's Institute of Dermatology, Faculty of Medicine and Life Sciences, Kings College London, London, United Kingdom.
  • Schröder JM; Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
  • Weidinger S; Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany.
  • van den Bogaard E; Department of Dermatology, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
  • Soumelis V; Université de Paris, Inserm, U976 HIPI Unit, Institut de Recherche Saint-Louis, Paris, France; Laboratoire d'Immunologie et Histocompatibilité, AP-HP, Hôpital St Louis, Paris, France.
  • Greco D; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Institute of Biosciences and Medical Technologies (BioMediTech), Tampere, University, Finland; Institute of Biotechnology, University of Helsinki, Helsinki, Finland.
  • Barker J; St John's Institute of Dermatology, Faculty of Medicine and Life Sciences, Kings College London, London, United Kingdom.
  • Lauerma A; Department of Dermatology, Allergology and Venereology, Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Ranki A; Department of Dermatology, Allergology and Venereology, Inflammation Centre, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
  • Andersson B; Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
  • Alenius H; Department of Bacteriology and Immunology, University of Helsinki, Helsinki, Finland; Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
  • Homey B; Department of Dermatology, University Hospital Duesseldorf, Medical Faculty, Heinrich-Heine-University, Duesseldorf, Germany. Electronic address: bernhard.homey@med.uni-duesseldorf.d.
J Dermatol Sci ; 106(3): 132-140, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35537882
ABSTRACT

BACKGROUND:

Loss-of-function mutations in the filaggrin (FLG) gene directly alter skin barrier function and critically influence atopic inflammation. While skin barrier dysfunction, Th2-associated inflammation and bacterial dysbiosis are well-known characteristics of atopic dermatitis (AD), the mechanisms interconnecting genotype, transcriptome and microbiome remain largely elusive.

OBJECTIVE:

In-depth analysis of FLG genotype-associated skin gene expression alterations and host-microbe interactions in AD.

METHODS:

Multi-omics characterization of a cohort of AD patients carrying heterozygous loss-of-function mutations in the FLG gene (ADMut) (n = 15), along with matched wild-type (ADWt) patients and healthy controls. Detailed clinical characterization, microarray gene expression and 16 S rRNA-based microbial marker gene data were generated and analyzed.

RESULTS:

In the context of filaggrin dysfunction, the transcriptome was characterized by dysregulation of barrier function and water homeostasis, while the lesional skin of ADWt demonstrated the specific upregulation of pro-inflammatory cytokines and T-cell proliferation. S. aureus dominated the microbiome in both patient groups, however, shifting microbial communities could be observed when comparing healthy with non-lesional ADWt or ADMut skin, offering the opportunity to identify microbe-associated transcriptomic signatures. Moreover, an AD core signature with 28 genes, including CCL13, CCL18, BTC, SCIN, RAB31 and PCLO was identified.

CONCLUSIONS:

Our integrative approach provides molecular insights for the concept that FLG loss-of-function mutations are a genetic shortcut to atopic inflammation and unravels the complex interplay between genotype, transcriptome and microbiome in the human holobiont.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica / Proteínas Filagrinas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dermatite Atópica / Proteínas Filagrinas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article